Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Biotechnology

Healthcare
$42.53 -1.86%

-$0.62 today

Market cap
$800.84M
Beta
1.18
P/E (TTM)
1.7
EPS (TTM)
$19.78
52W Low $18.14High $52.24

Volume 0.24M

Average 0.36M

RIGL Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Rigel Pharmaceuticals, Inc.NASDAQ: RIGL

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin holds steady near 92.2%

Gross margin was 92.2% in Q1 FY2026, up 0.4 pp from a year earlier. On a trailing-twelve-month basis it was 93.4%, up 3.7 pp year over year. Over 3 fiscal years it narrowed by 5.2 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
92.2%+0.7 pp QoQ
Last fiscal yearDec 2025
93.3%+3.7 pp YoY
LTMMar 2026
93.4%+3.7 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.4 pp——
1 year+3.7 pp——
3 years-5.2 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
93.3%
Year-over-year change
+3.7pp

Gross Margin vs competitors

How RIGL compares with its peers on the latest reported figures

  • RIGL's LTM Mar 2026 gross margin of 93.4% is the 4th highest of the 8 companies compared; the peer median is 86.5%.
  • Its year-over-year change of +3.7 pp is the 3rd highest of 6, against a peer median of -0.1 pp.
  • Over three fiscal years its change of -5.2 pp compares with a peer median of -0.0 pp.
RIGL Competitors Peer median
Gross Margin for RIGL and competitors
Company Period LTM level YoY 3-year change
ANLAdlai Nortye Ltd.LTM Jun 2024100.0% ——
EXELExelixis, Inc.LTM Jul 202696.5% -0.1 pp-0.0 pp
CCCCC4 Therapeutics, Inc.LTM Mar 202694.8% +9.6 pp-22.2 pp
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202693.4% +3.7 pp-5.2 pp
NRIXNurix Therapeutics, Inc.LTM Aug 202686.5% +249.4 pp+455.2 pp
VSTMVerastem, Inc.LTM Mar 202683.7% -16.3 pp-17.1 pp
MREOMereo BioPharma Group plcLTM Mar 2026-105.7% ——
CRDFCardiff Oncology, Inc.LTM Mar 2026-2105.7% -548.4 pp+0.0 pp
CGEMCullinan Therapeutics, Inc.FY2025— ——
ALXOALX Oncology Holdings Inc.FY2025— ——
Peer median (excluding RIGL) 86.5%-0.1 pp-0.0 pp

Competitors are the stored peer set for RIGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue149.24M120.24M116.88M179.28M294.28M
Cost of Revenue1.08M1.75M7.11M18.65M19.62M
Gross Profit148.15M118.49M109.77M160.63M274.66M
Gross Margin99.3%98.5%93.9%89.6%93.3%
Research & Development65.24M60.27M24.52M23.38M33.3M
Selling, General & Admin91.89M112.45M105.74M113.06M115.9M
Operating Expenses160.65M174.04M130.26M136.44M149.2M
Depreciation & Amortization1.16M998K1.24M2.23M2.42M
EBITDA(11.29M)(53.87M)(16.98M)28.51M131.56M
EBITDA Margin-7.6%-44.8%-14.5%15.9%44.7%
Operating Income(12.5M)(55.55M)(20.49M)24.19M125.47M
Operating Margin-8.4%-46.2%-17.5%13.5%42.6%
Interest Income47K684K2.27M2.09M3.68M
Interest Expense4.86M3.71M6.87M7.92M7.32M
Other Income / Expenses(4.81M)(3.02M)(4.6M)(5.83M)(3.64M)
Income Before Tax(17.31M)(58.57M)(25.09M)18.37M121.83M
Pre-Tax Margin-11.6%-48.7%-21.5%10.2%41.4%
Income Tax Expense605K00881K(245.2M)
Net Income(17.91M)(58.57M)(25.09M)17.49M367.02M
Net Margin-12.0%-48.7%-21.5%9.8%124.7%
EPS (Basic)(1.10)(3.40)(1.44)0.9920.40
EPS (Diluted)(1.10)(3.40)(1.44)0.9919.48
Weighted Avg Shares17.05M17.24M17.4M17.58M17.99M
Weighted Avg Shares (Diluted)17.05M17.24M17.4M17.69M18.84M

Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Intrinsic Alpha fair value

Locked

Current Price

$42.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.